Amundi
CSTL icon

Amundi’s Castle Biosciences CSTL Stock Holding History

Amundi’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,137
Closed -$79.4K – 1789
2025
Q1 		$79.4K Buy
4,137
+4,111
+15,812% +$102K ﹤0.01% 1774
2024
Q4 		$851 Buy
+26
New +$792 ﹤0.01% 2042
2022
Q1 		– Sell
-2,350
Closed -$87K – 1657
2021
Q4 		$87K Buy
2,350
+1,689
+256% +$88.3K ﹤0.01% 1584
2021
Q3 		$44K Buy
+661
New +$46.5K ﹤0.01% 1535

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Amundi's CSTL Position: Q2 2025 in Review

Amundi sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 4,137 shares — an estimated $79.4K sold.

Amundi first reported a position in CSTL in Q3 2021 and held it in 4 quarters. The position peaked at $87K in Q4 2021. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Amundi reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 4,137 Castle Biosciences shares in Q2 2025, an estimated $79.4K.
  • Amundi first reported a position in Castle Biosciences in Q3 2021 and held it in 4 quarters.
  • Amundi's Castle Biosciences position peaked at $87K in Q4 2021.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.